(349) Shining a Light on Women's Sexual Health: Insights from Patients Presenting with Sexual Dysfunction

Abstract

Abstract Introduction Sexual health is an essential component of overall health and wellbeing, and its importance in women's lives has often been neglected in clinical practice due to cultural, social, and educational barriers. Fortunately, in recent years, there has been a growing awareness and emphasis on women's sexual health, with increasing research attention dedicated to addressing this issue. Objective In this context, this study aims to contribute to the growing body of knowledge on women's sexual health by examining the characteristics of women who present for treatment of sexual dysfunction. Methods Women who presented with sexual dysfunction to our clinic from July 2022 to June 2023 were enrolled in this study and administered the PHQ-9 and FSFI surveys. In addition, hormone levels, demographic data, and pertinent medical history were collected at this time. Descriptive statistics and logistic regression analyses were used to identify factors associated with presentation for treatment. Results A total of 26 women with a mean age of 52 (SD=2.4) participated in this study. 10 (38.5%) women presented with low estradiol levels, and 4 (15.4%) women with low testosterone, although mean levels thereof were 53.7 (SD=18.9) and 72 (SD=16.8), respectively. Most women (15, 57.7%) reported mild to moderate depressive symptoms on PHQ-9 with a mean score of 7.53 (SD=1.08), but only 2 reported a formal diagnosis of depression. Somewhat expectedly, 24 (92.3%) women report an FSFI score less than 26 (mean=17.9, SD=1.63), corroborating their subjective experience. Additionally, logistic regression demonstrates that depressive symptoms have a strong relationship (R=0.63) with increased pain during intercourse (p=0.014) and decreased sexual satisfaction (p=0.002). Conclusions These results provide valuable insights into the characteristics of women who present for treatment of sexual dysfunction. The findings suggest that low hormone levels, particularly estradiol, may be a contributing factor to sexual dysfunction in some women. The high prevalence of depressive symptoms reported in our study highlights the need for clinicians to recognize and address the mental health concerns of these patients as well. It also underscores the importance of comprehensive sexual health assessments, including hormone level evaluations and mental health screenings, in the management thereof, though our findings are limited by a small sample size and lack of follow up and further studies are still needed. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: AbbVie, Marius, Tolmar, Endo, Petros, Boston Scientific, Coloplast.